Desmethyl sibutramine Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: Vendor-neutral scientific reference catalog

Active sibutramine metabolite; arylcyclobutylalkylamine; monoamine reuptake inhibitor compound Reference needs_revision Best effort · source review pending

Also known as: N-Desmethylsibutramine, mono-desmethylsibutramine, N-monodesmethylsibutramine, Norsibutramine, BTS-54354, BTS 54 354, 1-[1-(4-chlorophenyl)cyclobutyl]-N,3-dimethylbutan-1-amine

Open in Calculator ← Compound Index All Tools

Best-effort research profile: this record has not passed full two-source scientific verification. Descriptive fields, research protocols, storage/handling notes, and interaction guidance below are shown with their evidence labels, but calculator presets and exact dosing math remain hidden until the record is verified or reaches Community-Supported status.

Quick Facts

Reference Sizes

Not standardized / source review pending

Best-Effort Research Profile

Desmethyl sibutramine, also called N-desmethylsibutramine or metabolite M1, is a molecularly defined sibutramine metabolite with the formula C16H24ClN. It is structurally related to sibutramine and has been characterized as a pharmacologically active metabolite involved in inhibition of norepinephrine and serotonin reuptake. The compound has also been identified analytically in adulterated weight-loss products.

Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.

Research Profile

Half-Life

For sibutramine-treated human subjects, the FDA label reports an elimination half-life of approximately 14 hours for metabolite M1; this value describes M1 formed after administration of sibutramine and is not an independently established half-life for administration of isolated desmethylsibutramine.

Reported Research Effects

Active monoamine reuptake inhibition involving norepinephrine and serotonin transport systems is reported for sibutramine metabolite M1 in FDA pharmacology documentation.
In animal pharmacology research, enantiomer-specific anorectic, locomotor, and monoamine-uptake effects were evaluated for desmethylsibutramine; these findings are preclinical and do not establish a clinical use or safety profile for isolated desmethylsibutramine.
The compound has been used as an analytical target in LC-MS/MS, ion-mobility, and other forensic methods for detecting adulteration of weight-loss products.

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Notes

Research references include an animal study evaluating R(+) and S(-) desmethylsibutramine at 2.5-10 mg/kg intraperitoneally in rats for anorectic and locomotor endpoints, and 0.1-2.5 mg/kg intraperitoneally for a forced-swim behavioral endpoint. These are historical experimental animal regimens, not human-use instructions. Human pharmacokinetic information located in the FDA sibutramine label concerns formation of M1 following oral sibutramine administration; no reliable isolated-desmethylsibutramine human dosing, administration, onset, solubility, or storage specifications were established from the authoritative sources reviewed.

Supplementary research context only. Not medical advice or a treatment recommendation.

Registry Identifiers

PubChem CID 10199199; CAS RN 168835-59-4; FDA UNII 889I657R9P; EPA DSSTox ID DTXSID701314239; HMDB ID HMDB0251062; molecular formula C16H24ClN; molecular weight 265.82 g/mol; IUPAC name 1-[1-(4-chlorophenyl)cyclobutyl]-N,3-dimethylbutan-1-amine; InChIKey PLXKZKLXYHLWHR-UHFFFAOYSA-N; InChI InChI=1S/C16H24ClN/c1-12(2)11-15(18-3)16(9-4-10-16)13-5-7-14(17)8-6-13/h5-8,12,15,18H,4,9-11H2,1-3H3; canonical structure string CC(C)CC(C1(CCC1)C2=CC=C(C=C2)Cl)NC

Source-Backed Observations

PubChem records desmethylsibutramine as a known human metabolite of sibutramine. FDA documentation identifies sibutramine metabolites M1 and M2 as pharmacologically active and describes M1 as the secondary-amine metabolite. FDA laboratory notifications have reported desmethylsibutramine in adulterated weight-loss products. The isolated compound should not be conflated with sibutramine or with the N-didesmethyl metabolite M2.

Reflects published research. Educational reference — not a recommendation for use.

Sources Under Review

N-Desmethylsibutramine, PubChem CID 10199199
https://pubchem.ncbi.nlm.nih.gov/compound/10199199 (accessed 2026-09-13)

The Structure of Sibutramine and Its Metabolites
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020632a_cmc_thru_pharmtox.pdf (accessed 2026-09-13)

Meridia sibutramine hydrochloride capsules prescribing information
https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/20632s8s11LBL.pdf (accessed 2026-09-13)

Public Notification: Exhilarate contains hidden drug ingredients
https://www.fda.gov/drugs/medication-health-fraud/public-notification-exhilarate-contains-hidden-drug-ingredients (accessed 2026-09-13)

Enantioselective behavioral effects of sibutramine metabolites
https://pubmed.ncbi.nlm.nih.gov/10844103/ (accessed 2026-09-13)

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.